NeuroSense Therapeutics (NRSN) said Monday it has signed a binding term sheet with an unnamed pharmaceutical company to further develop PrimeC as potential treatment for amyotrophic lateral sclerosis in some key markets.
NeuroSense said it would keep full rights to PrimeC in other key territories.
The term sheet includes a "substantial" upfront payment" and funding for a phase 3 study as well as milestone payments and royalties on annual net sales, NeuroSense said.
A definitive agreement is expected to be finalized in Q1 2025, the company added.
NeuroSense's shares were down more than 16% in early trading Monday.
Price: 1.13, Change: -0.23, Percent Change: -16.91
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。